Pfizer Inc
PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Aug 4, 2026Score 11/3056% above fair value
$30.52+0.57 (+1.90%)
Close on Oct 30, 2026Market cap $173.95BP/E 40.2Yield 5.64%
Pfizer Remaining Performance Obligations (RPO) by Year
Remaining Performance Obligations (RPO) — Paxlovid multi-year contracts ($M) ($M)
Pfizer Remaining Performance Obligations (RPO): $1,000M in FY2025, unchanged from a year earlier.
Latest, FY2025
1,000
Period ended Dec 31, 2025
Change on a year earlier
0.0%
1,000 in FY2024
History
3 years
Since FY2023
Sources
3
Documents cited below
Where the FY2025 figure comes from
Source: Form 10-K (filed 2026-02-26) ↗
Reported in Form 10-Q / 10-K Revenue Note.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Remaining Performance Obligations (RPO) — Paxlovid multi-year contracts ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1,000 | 0.0% | Form 10-K (filed 2026-02-26) ↗ |
| FY2024 | Dec 31, 2024 | 1,000 | -70.6% | Form 10-K (filed 2025-02-27) ↗ |
| FY2023 | Dec 31, 2023 | 3,400 | – | Form 10-K (filed 2024-02-22) ↗ |
Cite this data
StockData. (2026). Pfizer Remaining Performance Obligations (RPO) ($M), annual FY2023–FY2025 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/rpo-paxlovid
See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.